Walter R Holmsten, MD | |
7545 S Braeswood Blvd, Houston, TX 77071-1423 | |
(713) 777-3131 | |
(713) 777-5544 |
Full Name | Walter R Holmsten |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 24 Years |
Location | 7545 S Braeswood Blvd, Houston, Texas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124050596 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | L8734 (Texas) | Primary |
2083X0100X | Preventive Medicine - Occupational Medicine | L8734 (Texas) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Holmsten Family And Occupational Medicine | 4789910530 | 2 |
News Archive
Fad diets and exercise routines seem to come and go as often as the refrigerator calls out to people looking to lose a few pounds.
APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
› Verified 6 days ago
Entity Name | Charles G Holmsten |
---|---|
Entity Type | Practitioner - Family Practice |
Entity Identifiers | NPI Number: 1083728711 PECOS PAC ID: 7810045358 Enrollment ID: I20090511000338 |
News Archive
Fad diets and exercise routines seem to come and go as often as the refrigerator calls out to people looking to lose a few pounds.
APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
› Verified 6 days ago
Entity Name | Holmsten Family & Occupational Medicine |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1386131746 PECOS PAC ID: 4789910530 Enrollment ID: O20190731002864 |
News Archive
Fad diets and exercise routines seem to come and go as often as the refrigerator calls out to people looking to lose a few pounds.
APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Walter R Holmsten, MD 7545 S Braeswood Blvd, Houston, TX 77071-1423 Ph: (713) 777-3131 | Walter R Holmsten, MD 7545 S Braeswood Blvd, Houston, TX 77071-1423 Ph: (713) 777-3131 |
News Archive
Fad diets and exercise routines seem to come and go as often as the refrigerator calls out to people looking to lose a few pounds.
APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
› Verified 6 days ago
Dr. Joseph G Nevarez, MD Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 6411 Fannin St, Hyperbaric & Wound Care Center, Houston, TX 77030 Phone: 713-704-5900 | |
Dr. William Farrington Miller, MD, MPH Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1661 Tanglewood Blvd, Houston, TX 77056 Phone: 713-622-8100 Fax: 713-961-2958 | |
Elizabeth C Frenzel, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1515 Holcombe Blvd, Houston, TX 77030 Phone: 713-792-6161 | |
Dr. Jeffrey D. Britton, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2646 S Loop W Ste 550, Houston, TX 77054 Phone: 281-513-1884 | |
Cedrick Smith, MD Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 N Post Oak Rd, Houston, TX 77055 Phone: 615-778-4066 Fax: 615-778-9114 | |
Dr. Monica Andrea Clark-reed, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 11160 Fondren Rd, Houston, TX 77096 Phone: 832-530-4444 Fax: 832-683-4133 | |
Oluwatoyosi Olumide, Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2201 Arbor St, Houston, TX 77004 Phone: 833-430-4807 |